Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $336.00

Krystal Biotech (NASDAQ:KRYS) had its price target lifted by equities research analysts at Citigroup from $320.00 to $336.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 23.08% from the company’s previous close.

Several other equities research analysts have also issued reports on KRYS. HC Wainwright reissued a “buy” rating and set a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday. TD Cowen upped their price objective on shares of Krystal Biotech from $202.00 to $306.00 and gave the stock a “buy” rating in a research report on Friday. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Friday. Bank of America increased their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Chardan Capital lifted their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $263.88.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded up $11.58 during mid-day trading on Monday, reaching $272.99. 412,535 shares of the company’s stock were exchanged, compared to its average volume of 325,644. The firm has a market capitalization of $7.92 billion, a price-to-earnings ratio of 40.93 and a beta of 0.46. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $274.40. The firm has a 50-day moving average price of $227.55 and a two-hundred day moving average price of $182.91.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The company had revenue of $97.80 million during the quarter, compared to the consensus estimate of $93.72 million. As a group, sell-side analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently modified their holdings of the stock. Hantz Financial Services Inc. boosted its position in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the last quarter. Bessemer Group Inc. raised its holdings in Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the period. AdvisorNet Financial Inc purchased a new position in shares of Krystal Biotech during the 3rd quarter valued at about $30,000. Salomon & Ludwin LLC purchased a new stake in shares of Krystal Biotech in the third quarter worth $33,000. Finally, First Horizon Advisors Inc. increased its stake in Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.